Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
about
Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) miceKv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseasesImmune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceHeat shock protein bystander antigens for peptide immunotherapy in autoimmune diseaseRecombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes caseGenetics, pathogenesis and clinical interventions in type 1 diabetesThe role of TNF-α in mice with type 1- and 2- diabetesDevelopment of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis.2011 Update: antigen-specific therapy in type 1 diabetesGenetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes.Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model.Insulin as a key autoantigen in the development of type 1 diabetesBanting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells.Ins2 deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin.Immunotherapy of type 1 diabetes: where are we and where should we be going?Mixed lineage kinase-3 stabilizes and functionally cooperates with TRIBBLES-3 to compromise mitochondrial integrity in cytokine-induced death of pancreatic beta cellsSubcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma.Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionDistinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3+ regulatory T cells in humans and mice.Evaluating preclinical efficacy.Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.Review article: autoimmune hepatitis -- current management and challenges.Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons.An update on the use of NOD mice to study autoimmune (Type 1) diabetes.Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cellsInduction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD miceTransient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice.Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.Challenges in the pursuit of immune tolerance.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice.Noninsulin pharmacological management of type 1 diabetes mellitusCombining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation.Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice
P2860
Q21562482-EE406D5E-D52A-428E-9D05-682ADFD1AAA0Q24676659-2E7D4F5E-30EB-43B3-A32C-80814BCDEE99Q26850621-35E7A943-6889-439F-827D-79E864F7F333Q27008837-C74A5FC6-88C1-4982-A259-6BB0BCD80034Q27028100-E9A7FAC1-9520-4B30-90BE-82EC102FB6B5Q28281029-DEEC9EAE-CE6D-4A5F-9197-64C753E1DDDAQ28730016-CF787D04-1136-42F7-B742-7F731FD2917CQ30413598-34E72FDA-35B0-4C36-BA07-533C1352B70CQ30491507-2B7BE65B-ACA4-448D-A26D-B1A22A8D3EE1Q33267344-B857FC5B-D810-4ACE-A17F-8E36130A5BA3Q33593629-9FF2D27D-5747-409A-8CDA-9EAE9F4A1322Q33636716-1DE76995-EE5D-44E7-970A-B45A1A4A6646Q33646749-CF9648F8-EF01-48A3-ABEA-A52612E117DFQ33712227-21BDADA3-DB59-4BC2-91D9-8A53C4B97C28Q33750667-5718DA80-6499-4D14-8039-770567493956Q33750748-59C36629-A318-4723-9413-43CA58FC8005Q33805693-BF1D2484-E231-4615-AD3D-96A67BB91F1BQ33815506-8B5CA09F-1506-4A78-A420-B74A216EBB1BQ33991071-BC1042AE-6ED9-4DDB-BEA3-1DDEFBEF9680Q34023585-0CE1A3DF-E77C-43B7-A655-42D572D5CD33Q34082782-D47DDCC5-5183-4DD4-9086-A59DB4BA1386Q34096519-9863E1A6-D23F-41D1-BB0B-8A2DC47C5335Q34175958-3C14F3C1-995A-42DE-983A-2760EC7D74A1Q34207966-3A938803-DBF4-4048-A99C-BFBA5E20F6C9Q34208736-AAC315A9-E6FB-484A-8CAC-C71B377EDE0AQ34318993-25D5C660-A19A-453A-A597-65A14C6B8597Q34369116-CA4F1E36-9E94-479C-ADC2-A476E74F19FDQ34375578-8F181ECE-7F77-4461-8B64-3716FF39B8FCQ34508281-78958395-7357-4BF6-979B-270961BF863CQ34512471-3CF3B2AB-7775-4B39-939A-F6B6279B9B81Q34527126-C6FF0448-85FC-4ED2-95E6-A98E632F9514Q34583970-0D7DBE7C-9B29-4BE4-8EC8-3B4FD945B421Q34630923-6BD92D79-F19C-4344-81B4-10D5A2E303D8Q34974448-21AF8619-512D-4327-B1F3-3E6ABE50FA81Q35116303-272F6BB4-93AF-4F9F-A49C-FCCC28934191Q35146734-710B2A7B-15BE-46F3-B959-4E2D85AC3BDFQ35153044-D032806D-E804-4930-AF82-89CA6423DBACQ35288471-3187EE29-BD4E-4ADB-9234-BAAF8AF1BE54Q35612451-9A49B39E-4FB1-4269-87FD-09AD1805CC3BQ35616760-F2268C1B-CB8C-4004-8C5C-149682DD2541
P2860
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@ast
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@en
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@nl
type
label
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@ast
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@en
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@nl
prefLabel
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@ast
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@en
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@nl
P2093
P2860
P356
P1476
Anti-CD3 and nasal proinsulin ...... une diabetes by inducing Tregs
@en
P2093
Damien Bresson
Evelyn Rodrigo
Jeffrey A Bluestone
Kevan C Herold
Lisa Togher
Matthias von Herrath
P2860
P304
P356
10.1172/JCI27191
P407
P577
2006-04-20T00:00:00Z